
    
      A multicenter Open-label, single-arm, phase I/II clinical trial is conducted on patients with
      histological stage IV Pancreatic cancer given gemcitabine plus S-1. The usefulness of this
      regimens as 1st line therapy for pancreatic cancer was evaluated by the disease-free
      survival(DFS), median survival time (MST), incidence and severity of adverse event.
    
  